Circulating Blood-Based Biomarkers in Pulmonary Hypertension
暂无分享,去创建一个
A. Torbicki | M. Florczyk | M. Kurzyna | P. Kędzierski | Szymon Darocha | A. Pietrasik | M. Banaszkiewicz | A. Gąsecka | Michał Piłka
[1] K. Filipiak,et al. Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes , 2021, Journal of inflammation research.
[2] W. Klepetko,et al. Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension , 2021, Circulation. Cardiovascular interventions.
[3] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2021, Revista espanola de cardiologia.
[4] M. Humbert,et al. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs , 2021, European Respiratory Journal.
[5] A. Torbicki,et al. Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension , 2021, Journal of clinical medicine.
[6] A. Torbicki,et al. Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension , 2021, Journal of clinical medicine.
[7] A. Torbicki,et al. Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty , 2021, Diagnostics.
[8] Xiaoxuan Sun,et al. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study , 2020, BMC Pulmonary Medicine.
[9] C. Hamm,et al. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension , 2020, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[10] A. Torbicki,et al. Soluble ST2 protein as a new biomarker in patientswith precapillary pulmonary hypertension , 2020 .
[11] C. Jung,et al. Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH). , 2020, Heart, lung & circulation.
[12] J. Roos‐Hesselink,et al. The Prognostic Value of Soluble ST2 in Adults with Pulmonary Hypertension , 2019, Journal of clinical medicine.
[13] R. Benza,et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.
[14] H. Ghofrani,et al. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension , 2019, Circulation.
[15] A. Torbicki,et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. , 2019, International journal of cardiology.
[16] A. Torbicki,et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. , 2019, The Lancet. Respiratory medicine.
[17] G. Guerra,et al. Pulmonary Hypertension and Obesity: Focus on Adiponectin , 2019, International journal of molecular sciences.
[18] A. E. van den Bosch,et al. The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi‐biomarker approach , 2019, American heart journal.
[19] G. Simonneau,et al. An overview of the 6th World Symposium on Pulmonary Hypertension , 2019, European Respiratory Journal.
[20] C. Hamm,et al. Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension , 2018, PloS one.
[21] A. Cieślewicz,et al. Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension , 2018, Respiration.
[22] N. Smedira,et al. Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension , 2018, PloS one.
[23] K. Fukuda,et al. Adiponectin in Chronic Thromboembolic Pulmonary Hypertension. , 2018, Circulation journal : official journal of the Japanese Circulation Society.
[24] J. Kutsch,et al. The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study , 2017, BMC Pulmonary Medicine.
[25] C. Hamm,et al. N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[26] B. Horne,et al. Galectin-3 Levels Are Elevated and Predictive of Mortality in Pulmonary Hypertension. , 2017, Heart, lung & circulation.
[27] A. Komosa,et al. Red Blood Cells Distribution Width as a Potential Prognostic Biomarker in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. , 2017, Heart, lung & circulation.
[28] P. Laveneziana,et al. Cardiopulmonary Exercise Testing in Pulmonary Hypertension , 2017, Annals of the American Thoracic Society.
[29] G. Krombach,et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience , 2017, European Respiratory Journal.
[30] T. Fukuda,et al. Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. , 2017, European journal of radiology.
[31] A. Torbicki,et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension , 2017, European heart journal.
[32] H. Honda,et al. Balloon pulmonary angioplasty improves interventricular dyssynchrony in patients with inoperable chronic thromboembolic pulmonary hypertension: a cardiac MR imaging study , 2017, The International Journal of Cardiovascular Imaging.
[33] S. Miyata,et al. Effects of Balloon Pulmonary Angioplasty on Oxygenation in Patients With Chronic Thromboembolic Pulmonary Hypertension - Importance of Intrapulmonary Shunt. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[34] S. Kushwaha,et al. Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. , 2016, The American journal of cardiology.
[35] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[36] K. Brown,et al. Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension , 2016, Heart and Vessels.
[37] M. Murata,et al. Balloon pulmonary angioplasty attenuates ongoing myocardial damage in patients with chronic thromboembolic pulmonary hypertension. , 2016, International journal of cardiology.
[38] G. Hansmann,et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension , 2016, Heart.
[39] Wang Wang,et al. Red cell distribution width is increased in chronic thromboembolic pulmonary hypertension , 2016, The clinical respiratory journal.
[40] Kaixiong Liu,et al. The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension , 2015, Journal of Thrombosis and Thrombolysis.
[41] S. Hokimoto,et al. The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction , 2015, ESC heart failure.
[42] R. D. de Boer,et al. Galectin-3 and post-myocardial infarction cardiac remodeling. , 2015, European journal of pharmacology.
[43] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[44] T. Mueller,et al. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[45] F. Xiao,et al. Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case control study , 2015, BMC Pulmonary Medicine.
[46] T. Mueller,et al. Soluble ST2 in heart failure. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[47] C. Carda,et al. Role of Circulating miRNAs as Biomarkers in Idiopathic Pulmonary Arterial Hypertension: Possible Relevance of miR-23a , 2015, Oxidative medicine and cellular longevity.
[48] Masaharu Kataoka,et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. , 2014, JACC. Cardiovascular interventions.
[49] Z. Jing,et al. Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension. , 2014, International journal of cardiology.
[50] W. Klepetko,et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients , 2014, European Respiratory Journal.
[51] Sanjiv J. Shah,et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. , 2014, American heart journal.
[52] Zhi-Hong Liu,et al. Plasma Soluble ST2 Levels Correlate With Disease Severity and Predict Clinical Worsening in Patients With Pulmonary Arterial Hypertension , 2014, Clinical cardiology.
[53] Woochul Chang,et al. Therapeutic implications of microRNAs in pulmonary arterial hypertension , 2014, BMB reports.
[54] K. Dimopoulos,et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value , 2014, Heart.
[55] A. Wiczkowski,et al. Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease , 2013, BMC Cardiovascular Disorders.
[56] F. Pinto,et al. An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[57] T. Welte,et al. Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension , 2013, Respiratory Research.
[58] W. Kraus,et al. Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes , 2013, Circulation. Heart failure.
[59] Naoki Sato,et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. , 2013, International journal of cardiology.
[60] D. Bonaduce,et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. , 2013, International journal of cardiology.
[61] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[62] C. Ayers,et al. Association of cardiac troponin I with disease severity and outcomes in patients with pulmonary hypertension. , 2013, The American journal of cardiology.
[63] D. J. Veldhuisen,et al. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH , 2013, Circulation. Heart failure.
[64] J. McMurray,et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). , 2012, American heart journal.
[65] A. Zwinderman,et al. Plasma brain natriuretic peptide as a biomarker for haemodynamic outcome and mortality following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. , 2012, Interactive cardiovascular and thoracic surgery.
[66] M. Humbert,et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. , 2012, Chest.
[67] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[68] C. Carroll,et al. Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis , 2012, Emergency Medicine Journal.
[69] Ayhan Cevik,et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease , 2012, Pediatric Cardiology.
[70] Ernesto Alfaro-Moreno,et al. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension , 2012, European Respiratory Journal.
[71] Fabio Martelli,et al. microRNAs as peripheral blood biomarkers of cardiovascular disease. , 2011, Vascular pharmacology.
[72] S. Hazen,et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension , 2011, European Respiratory Journal.
[73] S. Manzano-Fernández,et al. Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.
[74] D. Shao,et al. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. , 2011, Pharmacological research.
[75] J. Rehfeld,et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. , 2011, JAMA.
[76] J. Wharton,et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension , 2011, Heart.
[77] T. Welte,et al. GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells , 2011, Respiratory research.
[78] R. Tuder,et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. , 2011, Chest.
[79] A. Wu,et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.
[80] C. Bode,et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension , 2011, Journal of Thrombosis and Thrombolysis.
[81] A. Khera,et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.
[82] D. Grenache,et al. Establishment of reference intervals for soluble ST2 from a United States population. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[83] A. Tedgui,et al. Microparticles: Key Protagonists in Cardiovascular Disorders , 2010, Seminars in thrombosis and hemostasis.
[84] R. Dweik,et al. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.
[85] R. Trembath,et al. Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension , 2010, Circulation.
[86] R. White,et al. Endothelin-1 induces pulmonary but not aortic smooth muscle cell migration by activating ERK1/2 MAP kinase. , 2010, Canadian journal of physiology and pharmacology.
[87] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[88] S. Blankenberg,et al. Copeptin improves early diagnosis of acute myocardial infarction. , 2010, Journal of the American College of Cardiology.
[89] Yue Li,et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. , 2010, European heart journal.
[90] G. Lippi,et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. , 2009, Archives of pathology & laboratory medicine.
[91] W. Grossman,et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[92] Sanjiv J. Shah,et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. , 2009, The American journal of cardiology.
[93] D. J. Veldhuisen,et al. Galectin‐3: a novel mediator of heart failure development and progression , 2009, European journal of heart failure.
[94] T. Nawrot,et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[95] B. Andersson,et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension , 2009, European Respiratory Journal.
[96] Takamitsu Nakamura,et al. Adiponectin is released from the heart in patients with heart failure. , 2009, International journal of cardiology.
[97] F. Laenger,et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.
[98] J. Struck,et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.
[99] W. Grossman,et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.
[100] G. Rabinovich,et al. Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.
[101] Sanjiv J. Shah,et al. Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension , 2008, Circulation.
[102] M. Olschewski,et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension , 2008, European Respiratory Journal.
[103] J. Struck,et al. Copeptin: clinical use of a new biomarker , 2008, Trends in Endocrinology & Metabolism.
[104] R. Berger,et al. Biological Serum Markers in the Management of Pediatric Pulmonary Arterial Hypertension , 2008, Pediatric Research.
[105] M. Wolzt,et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. , 2007, American journal of respiratory and critical care medicine.
[106] L. Wallentin,et al. Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality , 2007, Circulation.
[107] D. Lloyd‐Jones,et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.
[108] M. Pfeffer,et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. , 2007, Journal of the American College of Cardiology.
[109] M. Sabatine,et al. Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome , 2007, Circulation.
[110] Richard T. Lee,et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.
[111] T. Welte,et al. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension , 2007, European Respiratory Journal.
[112] B. Hartmann,et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. , 2007, Chest.
[113] M. Olschewski,et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. , 2006, European heart journal.
[114] R. Lutter,et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[115] C. Denton,et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.
[116] A. Torbicki,et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.
[117] J. Struck,et al. Proteolytic processing pattern of the endothelin-1 precursor in vivo , 2005, Peptides.
[118] H. Schäfers,et al. Circulating big endothelin-1: an active role in pulmonary thromboendarterectomy? , 2005, The Journal of thoracic and cardiovascular surgery.
[119] D. Fliser,et al. Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[120] H. Schäfers,et al. Cytokine response to pulmonary thromboendarterectomy. , 2004, Chest.
[121] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[122] G. Fonarow,et al. Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.
[123] A. Torbicki,et al. Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.
[124] D. Fuchs,et al. Potential role of immune system activation-associated production of neopterin derivatives in humans , 2003, Inflammation Research.
[125] R. Ross,et al. ATS/ACCP statement on cardiopulmonary exercise testing. , 2003, American journal of respiratory and critical care medicine.
[126] Fred S Apple,et al. Predictive Value of Cardiac Troponin I and T for Subsequent Death in End-Stage Renal Disease , 2002, Circulation.
[127] Richard T. Lee,et al. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.
[128] M. Ando,et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. , 2002, The Annals of thoracic surgery.
[129] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.
[130] M. Uematsu,et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[131] J. Hohlfeld,et al. Hyperuricaemia in patients with right or left heart failure. , 1999, The European respiratory journal.
[132] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[133] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[134] N. Arnold,et al. MicroRNA-1405 p and SMURF 1 regulate pulmonary arterial hypertension , 2018 .
[135] L. Wallentin,et al. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. , 2017, Clinical chemistry.
[136] A. Torbicki,et al. Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. , 2017, Kardiologia polska.
[137] Volkmar Falk,et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.
[138] M. Yılmaz,et al. Usefulness of admission red cell distribution width as a predictor of early mortality in patients with acute pulmonary embolism. , 2012, The American journal of cardiology.
[139] H. Shimokawa,et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[140] M. Humbert,et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. , 2007, Respiratory medicine.
[141] F. Martinez,et al. ATS/ACCP Statement on cardiopulmonary exercise testing. , 2003, American journal of respiratory and critical care medicine.
[142] B. Groves,et al. Hyperuricemia in severe pulmonary hypertension. , 2000, Chest.
[143] A. Carayon,et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. , 1997, Cardiovascular research.
[144] C. Nathan. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon gamma. , 1986, Interferon.